Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511946 | 0.84 | MAOB (0.71) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL2095984 | 0.83 | MAOB (0.55) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL1252407 | 0.83 | CA2 (0.59) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL27776938 | 0.81 | CA2 (0.57) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL1027115 | 0.80 | KDM4E (0.62) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL735027 | 0.79 | MAOB (0.59) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL3147413 | 0.79 | MAOB (0.54) | MAOBCA2PSMB5PSMB8KDM4C | |
| Ammonia Solution, Strong SCHEMBL6385399 | 0.79 | KDM4E (0.60) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL4014824 | 0.79 | CA2 (0.55) | MAOBCA2PSMB5PSMB8CYP17A1 | |
| SCHEMBL18331257 | 0.79 | MAOB (0.54) | MAOBCA2PSMB5PSMB8KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | TEIJIN, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1477490-A1 | PYRROLOPYRIMIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAOB 3664/4885CA2 170/4885PSMB5 3988/4885 |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | MAOB 3976/4885CA2 1302/4885PSMB5 4255/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MAOB 3664/4885CA2 170/4885PSMB5 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.